Home » Stocks » BLRX

BioLineRx Ltd. (BLRX)

Stock Price: $2.32 USD 0.07 (3.11%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $2.35 +0.03 (1.29%) Nov 27, 4:58 PM

Stock Price Chart

Key Info

Market Cap 49.04M
Revenue (ttm) n/a
Net Income (ttm) -25.45M
Shares Out 21.14M
EPS (ttm) -1.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $2.32
Previous Close $2.25
Change ($) 0.07
Change (%) 3.11%
Day's Open 2.25
Day's Range 2.24 - 2.35
Day's Volume 461,533
52-Week Range 1.06 - 3.30

More Stats

Market Cap 49.04M
Enterprise Value 32.00M
Earnings Date (est) Mar 10, 2021
Ex-Dividend Date n/a
Shares Outstanding 21.14M
Float 21.17M
EPS (basic) -0.17
EPS (diluted) -1.97
FCF / Share -2.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.38M
Short Ratio 0.20
Short % of Float 6.53%
Beta 1.18
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.63
Revenue n/a
Operating Income -28.11M
Net Income -25.45M
Free Cash Flow -22.73M
Net Cash 17.03M
Net Cash / Share 0.81
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -32.04%
ROE -87.18%
ROIC -528.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(244.83% upside)
Current: $2.32
Target: 8.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.11-25.61-25.24-16.51-16.20-17.26-17.01-21.85-15.35
Net Income-25.45-22.96-24.35-15.84-14.40-11.08-17.02-20.43-13.13
Shares Outstanding14610989.9756.1451.4132.4322.4912.3612.36
Earnings Per Share-0.17-0.21-0.27-0.28-0.28-0.34-0.76-1.20-1.10
Operating Cash Flow-22.67-24.19-20.55-14.51-14.17-15.75-19.53-20.13-11.19
Capital Expenditures-0.07-0.17-0.34-0.05-2.68-0.19-0.09-0.16-0.25
Free Cash Flow-22.73-24.37-20.89-14.57-16.85-15.94-19.61-20.29-11.43
Cash & Equivalents27.4930.1549.4835.6247.6634.6818.2221.3825.87
Total Debt10.468.730.250.340.44--0.040.11
Net Cash / Debt17.0321.4249.2335.2847.2334.6818.2221.3425.76
Book Value33.3841.3252.8835.0347.6131.8111.7214.9822.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioLineRx Ltd.
Country Israel
Employees 42
CEO Philip Adam Serlin

Stock Information

Ticker Symbol BLRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BLRX
IPO Date July 25, 2011


BioLineRx, a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.